Lorbriqua 25mg Tablet
Marketer
Pfizer Ltd
Salt Composition
Lorlatinib (25mg)
Overview Lorbriqua 25mg Tablet
Brivanib 25mg tablets are indicated for adults with advanced, recurrent, or surgically inoperable non-small cell lung cancer (NSCLC). Its mechanism involves anaplastic lymphoma kinase (ALK) enzyme inhibition, specifically for patients exhibiting ALK genetic alterations. This medication is reserved for patients whose NSCLC has progressed despite prior treatment with other ALK inhibitors like alectinib or ceritinib. Brivanib 25mg is also efficacious against ALK-positive NSCLC with brain metastases. Administer with or without food, ideally at the same time daily. Dosage adjustments or temporary treatment interruptions may be necessary based on individual response and condition. Adhere strictly to the prescribed treatment duration; abrupt cessation is discouraged. Common adverse effects include peripheral edema (swelling in extremities), peripheral neuropathy (numbness/tingling in limbs), and cognitive impairment (confusion, memory loss, reduced concentration). Other potential side effects are dyspnea (shortness of breath), asthenia (fatigue), weight increase, arthralgia (joint pain), mood disturbances, and diarrhea. Report any concerning or worsening side effects to your physician for potential dose modification or supportive care. Prior to commencing treatment, inform your doctor of any pre-existing conditions such as cardiac or renal disease, depression, seizures, arrhythmias, respiratory issues, hypertension, hypercholesterolemia, or diabetes. Pregnant or lactating individuals require physician consultation before initiating therapy. Potential drug interactions exist; disclose all concurrent medications to your physician. A patient support/assistance program is available in India through Tata 1mg; contact your physician or call 1800-102-1618 for further information.
Primary Ingredients of Lorbriqua 25mg Tablet
No text provided. Please provide the text you wish me to rephrase.
Uses of Lorbriqua 25mg Tablet
Managing Non-Small Cell Lung Carcinoma
Major Benefits of Lorbriqua 25mg Tablet:
Follow your doctor's instructions precisely regarding dosage and treatment length for this medication. Ingest the 25mg Lorbriqua tablet whole; avoid chewing, crushing, or breaking it. This medication can be taken with or without food, though consistent timing is recommended.
Common Side effects of Lorbriqua 25mg Tablet:
- Fatigue
- Diarrhea
- Edema (swelling)
- High blood pressure
- Cough
- Joint pain
- Peripheral neuropathy (tingling and numbness of feet and hand)
- Weight gain
- Breathlessness
- Mood changes
- Hypercholesterolemia (high cholesterol)
- Increased triglyceride level in blood
How to use Lorbriqua 25mg Tablet:
Administer this medication precisely as your physician directs, adhering to both the prescribed dosage and treatment length. Ingest the tablet whole; avoid chewing, crushing, or fracturing it. The 25mg Lorbriqua tablet can be consumed with or without food, though consistent timing is recommended.
How Lorbriqua 25mg Tablet works:
Oncaspar 25mg tablets are an anticancer drug that inhibits the activity of a faulty protein responsible for cancer cell proliferation, thereby curbing or hindering tumor growth.
SAFETY ADVICE
AlcoholCONSULT YOUR DOCTOR
Alcohol consumption alongside Lorbriqua 25mg Tablet may pose unknown risks. Seek medical advice before combining them.
PregnancyCONSULT YOUR DOCTOR
Using Lorbriqua 25mg tablets during pregnancy may pose risks. While human research is scarce, animal studies indicate potential harm to the unborn child. A physician will assess the advantages against possible dangers prior to prescribing. Seek medical advice.
Breast feedingCAUTION
Use of Lorbriqua 25mg tablets during breastfeeding requires careful consideration. Mothers should discontinue breastfeeding for the duration of treatment and until the medication is fully cleared from their system.
DrivingCONSULT YOUR DOCTOR
The effect of Lorbriqua 25mg Tablet on driving ability is undetermined. Refrain from operating a vehicle if you exhibit symptoms impairing concentration or reaction time.
KidneyCAUTION
Exercise caution when administering Lorbriqua 25mg Tablets to individuals with severe kidney dysfunction; dosage modification may be necessary. Consult a physician for guidance. No dosage alteration is advised for patients exhibiting mild or moderate renal insufficiency.
LiverSAFE IF PRESCRIBED
Lorbriqua 25mg tablets are considered safe for patients with liver conditions; no dosage alteration is advised. Nevertheless, dosing guidelines for individuals with moderately or severely compromised liver function have yet to be determined.
What if you forget to take Lorbriqua 25mg Tablet :
NA
Facts to Know About Lorbriqua 25mg Tablet
| Label | Value |
|---|---|
| Chemical Type | Phenylpropanoids |
| Developing Good Habits | No. |
| Treatment Category | Cancer Medications |
| Actions | Kinase inhibitors targeting tyrosine |
3,018 People bought this recently